Xilio Therapeutics, Inc.
XLO
$0.71
-$0.03-4.44%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.07M | 8.08M | 2.93M | 1.72M | 2.26M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.07M | 8.08M | 2.93M | 1.72M | 2.26M |
| Cost of Revenue | 14.32M | 15.33M | -- | -- | 10.76M |
| Gross Profit | 4.75M | -7.25M | 2.93M | 1.72M | -8.50M |
| SG&A Expenses | 6.67M | 7.12M | 8.52M | 6.52M | 6.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.00M | 22.45M | 16.78M | 15.35M | 17.07M |
| Operating Income | -1.93M | -14.37M | -13.85M | -13.63M | -14.80M |
| Income Before Tax | -16.29M | -15.84M | -13.27M | -13.09M | -14.02M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.29M | -15.84M | -13.27M | -13.09M | -14.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.29M | -15.84M | -13.27M | -13.09M | -14.02M |
| EBIT | -1.93M | -14.37M | -13.85M | -13.63M | -14.80M |
| EBITDA | -1.59M | -13.99M | -13.35M | -13.25M | -14.42M |
| EPS Basic | -0.11 | -0.31 | -0.18 | -0.20 | -0.22 |
| Normalized Basic EPS | -0.07 | -0.19 | -0.11 | -0.13 | -0.14 |
| EPS Diluted | -0.11 | -0.31 | -0.18 | -0.20 | -0.22 |
| Normalized Diluted EPS | -0.07 | -0.19 | -0.11 | -0.13 | -0.14 |
| Average Basic Shares Outstanding | 144.11M | 51.83M | 74.70M | 64.68M | 63.47M |
| Average Diluted Shares Outstanding | 144.11M | 51.83M | 74.70M | 64.68M | 63.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |